Table 3.
Clinical studies addressing cardiovascular diseases.
| Component | Treatment | Disease | Patient Cohort | Outcome/Status | Number Clinical Trail |
|---|---|---|---|---|---|
| Elamipretide | 40 mg once daily for 28 ds | HF | Stable HF (NYHA II-III) LVEF < 45% |
Elamipretide was well tolerated but did not improve LVESV at 4 wks in patients with stable HFrEF compared with the placebo |
NCT02814097 [75] |
| Elamipretide | 20 mg once daily for 7 ds | HF | Patients hospitalized with congestion due to HF LVEF < 40% NT-proBNP >1500 pg/mL |
Unknown | NCT02914665 |
| mitoQ | 20 mg twice daily for 4 wks | Diastolic dysfunction due to ageing | Healthy patients between 50 to 75 years of age | Recruiting | NCT03586414 |
| mitoQ | 20 mg once daily for 8 wks | Hypertension | BP > 150/90 mmHg and BMI ≤ 40 kg/m2 | Recruiting | NCT05561556 |
| mitoQ | 40 mg daily for 12 mths | DCM | LVEF < 45% plasma NT-pro-BNP > 250 ng/L |
Recruiting | NCT05410873 |
| mitoQ | 20 mg daily for 4 wks | HFpEF | Stable HF (NYHA II-III) LVEF > 50% | Unknown | NCT03960073 |
| mitoQ | 10 mg on 2 ds separated by at least 72 h | CF | FEV1 percent predicted > 30% Resting O2 consumption > 90% |
Active, not recruiting | NCT02690064 |
| NAC | High dose twice daily for 2 ds | MI | ST-elevation infarction < 12 h Angina |
No benefit with respect to CIN and myocardial perfusion injury |
NCT00463749 [76] |
| NAC | 600 mg twice daily for 12 wks | HF | Stable HF (NYHA II-III) LVEF < 45% |
NAC significantly improved RV and LV systolic function in HFrEF compared to the placebo | IRCT20120215009014N333 [77] |
| SG1002 | 200 mg for 7 ds, then 400 mg for 7 ds, and then 800 mg for 7 ds | HF | Stable HF (NYHA II-III) LVEF < 40% |
SG1002 was well tolerated, and patients showed increased/stable H2S level |
NCT01989208 [78] |
Abbreviation: HF, heart failure; NYHA, New York Heart Association classification; LVESV, left ventricular end systolic volume; HFrEF, heart failure with reduced ejection fraction; BP, blood pressure; BMI, body mass index; DCM, dilated cardiomyopathy; NT-proBNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; CF, cystic fibrosis; FEV1, forced expiratory pressure in 1 s; MI, myocardial infarction; CIN, contrast induced nephropathy; H2S, hydrogen sulfide; O2, oxygen; mths, months; wks, weeks; ds, days; h, hours; mg, milligrams.